title: A tale of two receptors: insulin and insulin-like growth factor signaling in cancer.
abstract: Inhibition of the type I IGF receptor (IGF1R) has been the focus of numerous clinical trials. Two reports in this issue describe the results of phase I trials of an IGF1R tyrosine kinase inhibitor OSI-906. This commentary will describe the complex endocrine changes induced by these types of agents.
authors.affiliation: Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota yeexx006@umn.edu.
authors.forename: Douglas
authors.initials: D
authors.lastname: Yee
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D011719:Pyrazines